MP13-19 A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

Vignesh T. Packiam(Rutgers, The State University of New Jersey), Gary D. Steinberg(Rush University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), Alex Yeung(Genesys (United States)), Alexa Campanile, Ronald L. Davis(Wake Forest University), Karim Chamie(University of California, Los Angeles), A. Karim Kader(University of California San Diego), Donald L. Lamm(The University of Texas System)
The Journal of Urology
March 28, 2016
10.1016/j.juro.2016.02.2500
Cited by 9

Related Papers

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline
|The Journal of Urology|2012|487
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
|The Journal of Urology|2022|462
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459